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We  have  previously  reported  that  cell  cultures  transformed  by  oncogenic 
viruses develop a  two-stage fibrinolytic system whose activity is generated  by 
the interaction  of a  serum protein  and a  factor released  by transformed  cells 
(1, 2). The serum factor has been identified as the proenzyme plasminogen (3), 
and the cell factor is a  specific serine protease that functions as a  plasminogen 
activator (4). High levels of cell factor are released by avian and  mammalian 
fibroblasts transformed in vitro, and by primary cultures of malignant tumors, 
such  as  chemically  or  virally  induced  mammary  carcinomas.  Normal  fibro- 
blasts, and cultures of other normal control tissues, release little or no activator. 
To determine whether similar fibrinolytic activity is associated with human 
neoplasia,  we have studied  the properties  of three human tumor cell lines.  As 
shown below,  all  of these  cultures  produce high levels  of fibrinolytic activity 
and release proteins whose properties correspond to those found previously for 
plasminogen  activators  from  transformed  chicken,  rat,  hamster,  and  mouse 
cells (1-4). 
Materials and Methods 
The three lines of human neoplastic cells used were derived  respectively  from  an  osteo- 
sarcoma (RPMI-41), a mesothelioma (RPMI-212), and a malignant melanoma (RPMI-8352). 
The cells were cultured in plastic petri dishes (Falcon Plastics, Division of BioQuest, Oxnard, 
Calif.) using RPMI-1640 medium (Grand Island Biological Co., Grand Island, N. Y.) supple- 
mented with I0~ of fetal bovine serum. The cells were maintained  and subcultured  as pre- 
viously described (5). 
Human ceU cultures  of nonmalignant  origin were purchased from GIBCO; these included 
cultures  of embryonic skin, embryonic lung, and embryonic kidney.  Alternatively,  primary 
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cultures of human embryonic fibroblasts were prepared from fresh surgical material. The cells 
were cultured using the same conditions as described for the malignant  human cells. 
The preparation  of conditioned serum-free culture medium, the assay for fibrinolyfic ac- 
tivity, and the preparation of the protease iahibitors were as previously described (1-3). All 
determinations were performed in duplicate. The assay is based on the release of [z~sI]fibrin 
from the surface of petri dishes into the supernatant  solution; the solubilization of radioactivity 
depends on partial digestion of the insoluble fibrin. For assaying the effect of diisopropylphos- 
phofluoridate (DFP), conditioned medium was incubated with DFP (0.002 M) for 2 h, dia- 
lyzed overnight against 1,000 vol of Eagle's medium, and then assayed in the usual manner. 
A control sample was processed in the same way except that DFP was omitted. 
To test the effects of other presumed inhibitors of fibrinolysis, assays were performed in 
petri dishes containing  [l~I]fibrin (10Dg/cmP; total radioactivity 4 X 10  ~ clam). The inhibitor 
and a standard amount of conditioned medium were mixed, and the reaction started  by the 
addition of monkey serum to a final concentration of 2.5%. The vol was 1 ml and incubation 
was for 6 hr at 37°C. 
Partially purified cell factor (plasminogen activator) was isolated from conditioned medium 
according to the procedure of Unkeless et al. (4). The crude culture fluid containing  active cell 
factor was first clarified by centrifugation (5,000  g, 10 min) and then brought to pit 3.5 by the 
addition of 1 M HC1; solid ammonium sulfate (560 g/liter)  was added slowly with constant 
stirring at 4°C, and the precipitate was collected by centrifugation  (5,000 g, 10 min.) at 4°C. 
The precipitate was dissolved in the minimal volume of 0.005 M glycine-HC1  buffer, pH 2.3, 
and then was adsorbed to a column of SP-Sephadex (Pharmacia Fine Chemicals, Inc., Piscata- 
way, N. J.) as described by Unkeless et al. (4) ; after washing the column with 0.05 M ammo- 
nium acetate at pH 5.25 the cell factor was eluted with 0.2 M ammonium sulfate, pH 5.25. 
The pooled active fractions were then dialyzed against water and concentrated  to a small 
volume. Aliquots of these partially purified preparations were incubated with [3H]DFP (New 
England Nuclear, Boston, Mass.) (4°C, 24 h); control incubations  were performed in parallel 
without DFP, and samples of both were analyzed by SDS-polyacrylamide gel electrophoresis 
as described elsewhere (4, 6); the gels were cut into l-ram slices and these were assayed either 
for radioactivity  ([3H]DFP) or for cell factor (plasminogen activator)  activity (1, 4). 
RESULTS 
Fibrinolytic Activity Produced by Human Tumor Cell Lines.--Previous work 
with  nonhuman material has  shown  that  transformed cultures incubated in 
serum-free medium release a  plasminogen activator that promotes fibrinolysis 
when mixed with serum (1,  2). We have examined similar conditioned media 
from  human osteosarcoma,  melanoma, and mesothelioma cell lines for  their 
content of activator. The data in Table I  show that conditioned medium for 
each of the three cell lines produced fibrinolysis in the presence of  appropriate 
sera. Two elements were required for fibrinolysis; one of these was  contributed 
by the conditioned media and the other by the serum. Thus, neither medium 
alone, nor medium plus serum, nor conditioned medium alone produced fibrin- 
olysis; however, conditioned medium supplemented with the appropriate serum 
effectively hydrolyzed  the  radioactive fibrin. The  properties  of  conditioned 
media  from  human  tumor  cell  lines  therefore  resembled  those  previously 
reported for comparable materials from nonhuman cultures. 
Serum Specificity  of Fibrinolysis:  Activating and Inhibitory Sera.--One  im- 
portant characteristic of the fibrinolytic  activity produced by other transformed D.  B.  RIFKIN, J.  N.  LOEB, G.  MOORE, AND E.  REICH  1319 
TABLE I 
Serum Specificity of Fibrindytic Activity of Conditioned Medium from Human Tumor Cells 
Serum supplement 
Conditioned  medium tested: Radioactivity released 
Osteosarcoma*  Melanoma*  Mesothelioma~ 
% of total 
Dog  3.8  5.8  2.3 
Monkey  44.5  73.8  14.3 
Mouse  51.0  35.4  29.6 
Human (DBR)  57.3  78.0  12.4 
Fetal bovine  8.6  9.9  2.3 
Horse  24.3  50.1  5.3 
Fetal pig  2.6  1.17  1.8 
Bovine  20.7  39.4  NT§ 
Lamb  3.8  15.9  1.4 
Rat  10.0  7.9  5.6 
None  2.5  4.5  2.3 
RPMI  RPMI  RPMI 
None  2.5  1.9  1.5 
Mouse  1.9  2.3  1.4 
Petri dishes (35 ram)  containing [~sI]fibrin  (10 #g/cm  2) were prepared as described (1). 
Fresh or conditioned serum-free  RPML1640  (2 ml)  was mixed with the indicated serum 
supplement to yield a final serum concentration of 2.5%  (vol/vol), added to the [12sI]fibrin- 
coated plates, and incubated for 6 h at 37°C. The radioactivity  in the incubation medium was 
then measured. The melanoma-conditioned  medium was diluted 1:10 with RPMI-1640 before 
assay. 
* Total radioactivity 22,000 cpm/plate. 
J~ Total radioactivity 43,000 cpm/plate. 
§ NT, not tested. 
cultures was the apparent serum  specificity of the reaction; for each  type of 
cell, there was a  species-specific spectrum of activating and nonactivating sera 
(1-3). As also seen in Table I, the same was true for conditioned media  from 
the human  tumor  cell lines: monkey, mouse,  human,  bovine, and horse  sera 
were  activating, whereas  sera from rat, fetal bovine, dog, and fetal pig were 
nonactivating.  With  all of  the  transformed  cultures  previously investigated 
the  spectrum  of  activating sera was  species specific,  and  was  not influenced 
either by the nature of the transforming agent or by the tissue of origin.  One 
apparent inconsistency with previous results,  shown  by conditioned medium 
from one of the human  tumor cell lines, was the failure of horse serum to be 
activated by mesothelioma-conditioned medium.  This  resulted from  the fact 
that the mesothelioma cultures produced significantly less activator than  the 
other  two  cell lines,  as  reflected in  the  generally lower fibrinolysis obtained 
with all sera; the ability of this conditioned medium  to activate horse serum 1320  PROPERTIES  OF  PLASMINOGEN  ACTIVATORS 
was therefore detectable only after somewhat longer periods of incubation  (12 
h). 
The level of fibrinolysis was dependent on the concentration of both condi- 
tioned medium and serum in the assay mixture. When the conditioned medium 
was diluted (e.g., with RPMI-1640 medium) corresponding decreases in enzyme 
activity were produced  (Fig.  1).  The effect of changing serum concentrations 
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FzG. 1.  Conditioned serum-flee media from osteosarcoma and melanoma cell cultures were 
diluted as shown with RPMI and incubated in petri dishes (35 ram) containing [z~I]fibrin (10 
/~g/cm; total radioactivity 6 X  105 cpm). Final vol was 3 m], the serum concentration was 
2.5%, and incubation was in a CO~ incubator at 37°C. At the indicated times a]Jquots of the 
medium were removed and assayed for soluble radioactivity. The cm-ces labeled "conditioned 
medium" are controls incubated in absence of serum. 
was more complex (Table II). As the serum concentration  was progressively 
increased  the rate of fibrinolysis first increased,  then  reached  a  plateau,  and 
finally decreased.  We have analyzed this  result  and  have found  that  at low 
concentrations of serum, the rate of fibrinolysis was limited by the amount of 
serum factor, plasminogen. At the higher levels of serum, the rate of enzyme 
action was limited by the increasing concentration of serum protease inhibitors; 
this was shown by the effect of briefly exposing serum to mild acid (pH 3 for D.  B.  RI~'KIN, ~.  N.  LOEB~ G.  MOORE~ AND  E.  REICH  1321 
120 min), a treatment which inactivated the serum inhibitors.  1 This treatment 
abolished the inhibition of fibrinolysis previously seen at high serum concen- 
trations; the rate of fibrinolysis then became proportional to both the cell and 
serum factors  over  a  wide  concentration range for  each,  and permitted  the 
fibrinolytic assay to be used for purification of the human cell factor. 
It appeared likely that the low rates of fibrinolysis  observed with nonactivat- 
TABLE II 
Effect of Serum Concentration on Fibrinolysis by Conditioned Medium from Malignant Human 
Cdl Cultures 
Monkey serum  Conditioned  medium tested  Radioactivity  released 
% ~ot/~ol  % of total 
10  Osteosarcoma  3.2 
5  "  6.8 
2  "  31.6 
1  "  37.2 
0.5  "  36.4 
0.1  "  9.4 
None  "  2.6 
10  Melanoma  10.0 
5  "  34.9 
2  "  61.9 
1  "  66.0 
0.5  "  41.6 
0.1  "  8.0 
None  "  1.6 
10  Mesothelioma  5.2 
5  "  8.3 
2  "  17.0 
1  "  22.6 
0.5  "  17.0 
0.1  "  10.0 
None  "  1.0 
Petri dishes (35 mm) containing  [t2sI]fibrin  (10/~g/cm  2) were prepared as described. Condi- 
tioned medium (2 ml) was mixed with serum to yield the indicated fnal serum concentration 
and then incubated for 8 h at 37°C. The radioactivity in the incubation medium was deter- 
mined at the end of this period. Total radioactivity in each dish was 46,000 cpm. 
ing sera might be due to high concentrations of inhibitors, and therefore assays 
were performed with different serum mixtures to test for this (Table III). In 
all cases the addition of small amounts of nonactivating sera (e.g., dog serum) 
reduced the level of fibrinolysis  obtained in reactions with activating sera,  such 
as monkey serum. For example, the addition of dog serum (1%)  to an  assay 
of  osteosarcoma-conditioned medium  containing monkey  serum  (2.5%)  re- 
1 D. Loskutoff, unpublished observations. 1322  PROPERTIES  OF  PLASMINOGEN  ACTIVATORS 
TABLE III 
Effect of Inhibitory Sera on Fibrinotytic  Activity of Conditioned  Medium 
Concentration  of serum 
Monkey serum  Fetal bovine serum  Radioactivity  released into solution 
% voUvol  % vol/vol  % of total 
2.5  0  83.0 
2.5  1  65.0 
2.5  5  4.9 
2.5  10  3.2 
0  5  3.7 
Monkey serum  Dog serum  Radioactivity released into solution 
% vol/,ot  % vol/vol  % of total 
2.5  0  82.0 
2.5  !  15.8 
2.5  5  2.4 
2.5  10  1.5 
0  5  1.6 
Concentration of serum 
Monkey serum  Fetal pig serum  Radioactivity released into solution 
% vol/~ol  % ,oUvol  % of total 
2.5  0  100 
2.5  1  78 
2.5  5  4 
2.5  10  1.2 
0  2.5  1.5 
Petri dishes (35-ram diameter) containing [125I]flbrln  (10/~g/cm ~) were prepared as de- 
scribed previously. Serum supplements were added to conditioned medium from  tumor cell 
lines (2 ml) and the dishes incubated for 8 h at 37°C. The radioactivity  released into solution 
was then assayed. Total radioactivity:  A, 72,000 cpm; B, 40,000 cpm. 
duced the [125I]fibrin release from 82 %  to 15.8%. This inhibitory effect of non- 
activating sera was abolished by mild acid treatment, as was previously found for 
the inhibition occurring at high concentrations of activating sera (vide supra). 
Thus, the difference between activating and nonactivating sera was only quan- 
titative and reflected differences in the effective concentrations of protease in- 
hibitors. The  inhibitory effects of nonactivating sera could also be overcome 
by  increasing  concentrations  of  conditioned  medium,  i.e.,  plasminogen  acti- 
vator. 
Inhibitors  of  Fibrinolyt~c  Activity.--Fibrinolysis  stimulated  by  conditioned 
medium  from  human  cultures  was  inhibited  by  the  same  compounds  (1,  2) 
that had previously been found to inhibit the activity from other animal tumor 
cells.  The  concentrations  required  for  95 %  inhibition  of  fibrinolysis by  the 
combination  of osteosarcoma-conditioned medium  and  monkey  serum  (2.5 % D.  B.  RIFKIN,  J.  N.  LOEB,  G.  MOORE~  AND  ~... REICH  1323 
final concentration; conditions as in Table I)  were as follows: nitrophenyl-p- 
guanidobenzoate,  0.1  ~g/ml;  soybean trypsin  inhibitor,  20  /zg/ml;  e-amino 
caproic acid, 50 #g/ml; and sodium chloride, 0.5  M. Similar results were ob- 
tained  with melanoma-conditioned medium,  and  the  activity of  all  of  the 
conditioned media was abolished by 2 X  10  .-3 M DFP. 
Molecular Size and Activity of Human Cell Factor.--When conditioned media 
or partially purified cell factor were exposed to DFP, the ability to stimulate 
fibrinolysis by activating sera was irreversibly lost. This suggested  that  the 
cell factor in conditioned media probably contained an active serine residue 
that  could be labeled with  [3H]DFP  and thereby identified after SDS-poly- 
acrylamide  gel  electrophoresis.  Furthermore,  since  Christman  and  Acs  (7) 
found that the cell factor from transformed hamster cells was not inactivated 
by exposure to SDS, polyacrylamide gels could also be analyzed for catalyti- 
cally active cell factor. As seen in Fig. 2, partially purified cell factor prepara- 
tions contained two distinct components that stimulated fibrinolysis by mon- 
key serum. The mobility of the major component corresponded to a mol wt of 
48,000,  while that of the minor component was approximately 60,000. In elec- 
trophoretic mobility and size, the cell factors in melanoma-conditioned medium 
therefore resembled those produced by transformed mouse (4)  and  hamster 
(7)  cultures  (tool wt ~  50,000),  rather  than  that released  by  transformed 
chick (4) cells (tool wt ~  39,000). 
Both of the peaks found in the assays of catalytic activity were also visible 
in the radioactivity profile after reaction with [3H]DFP,  and both were there- 
fore serine enzymes; in addition, there were several lesser peaks of incorpo- 
rated [3H]DFP  that might indicate the presence of other serine enzymes in the 
conditioned medium. When the gel was assayed for fibrinolysis using purified 
human plasminogen the resulting activity profile was identical with that ob- 
tained using monkey serum. Thus, the human cell factor, like those found in 
transformed cultures from other species,  is a  serine protease that functions as 
a plasminogen activator. 
Fibrinolytic Activity of Nonmalignant Human Cells.--Several types of human 
cells derived from nonmalignant tissues have been tested for fibrinolytic activ- 
ity. Of the cultures listed in Table IV only the embryonic kidney cells were an 
established cell line, and the remainder were from early subcultures of primary 
cultures. Neither fibroblasts obtained from trypsinized embryos nor embryonic 
skin cells  showed significant fibrinolytic activity. Because cultures of normal 
kidney tissue have been reported to form the fibrinolytic activator urokinase 
(8),  the failure of the embryonic kidney cell line to show activity was unex- 
pected3  In contrast, cultures of normal embryonic lung cells  produced very 
Several other independently  isolated kidney cell lines have recently been tested and some 
of these do show serum-dependent  fibrinolysis.  The latter include  BHK, MDBK, and primary 
monkey  kidney cells as well as primary human embryonic  kidney cells purchased from Flow 
Laboratories, Inc., Rockville,  Md. and from Microbiological  Associates, Bethesda, Md. 1324  PROPERTIES  OF  PLASMINOGEN  ACTIVATORS 
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FIG. 2.  SDS-polyacrylamide gel electrophoresis  of human melanoma cell factor. Partially 
purified cell factor was inactivated with [SH]DFP  as described  in  the  text. The [SH]DFP- 
inactivated material and a control were dissolved in buffer containing 5% glycerol,  1% SDS, 
and 5% ethylene glycol and  applied to  a  slab  gel  (10%  acrylamide, 0.1%  SDS)  along 
with standard protein markers. The gel was cut into  separate lanes and these were  sliced 
and assayed either for radioactivity or for cell factor activity. 
high  levels  of  fibrinolysis,  but  some  of  this  was  independent  of serum  and 
might  therefore  have  been  due  to  the  action  of  other  proteases.  Further 
work will be required to characterize the nature of this activityJ 
Properties of Different Individual Human Sera.--Because  the fibrinolysis ob- 
served in culture might be related to cell function in the body, it was of inter- 
est to explore for possible differences in the ability of individual sera to generate 
s Several  additional independent cultures of cells derived from human embryonic lung, 
including WI38, have been assayed and all produce significant levels of fibrinolysis. Several of 
these release plasminogen  activator in culture (J. O'MaUey and D. Rifkin, unpublished ob- 
servations). D.  B.  RLFKIN,  J.  N.  LOEB~ G.  MOORE,  AND  E.  REICH  1325 
TABLE  IV 
Effects of Different Sera on Fibrinolytic  Activity of Nonmalignant Human Cell Cultures 
Serum supplement: 
Cell Type  Period of  No  Monkey  Dog  Human  Fetal 
Incubation  serum  bovine 
Radioactivity Released 
h  % of total 
Human embryonic fibroblasts  4  0.7  2.3  1.02  1.9  1.5 
16  2.3  5.3  2.8  5.2  2.8 
Human embryonic lung  4  21.2  75.4  56.5  81.0  46.2 
16  69.4  85.1  86.7  95.1  88.9 
Human embryonic skin  4  1.4  6.1  2.1  3.3  1.3 
16  4.6  12.3  7.2  9.9  3.8 
Human embryonic kidney  4  0.7  1.2  1.3  1.7  .9 
16  2.0  3.0  2.9  4.1  3.7 
Medium alone  4  0.5  0.5  0.8  0.4  0.5 
16  1.3  1.2  1.9  1.2  1.4 
Cells were plated in Eagle's medium containing 10°~ of fetal bovine serum in 60-mm petri 
dishes coated with [lesI]fibfin (10 ~tg/cm  ~) and allowed to settle for 4 h. The medium was then 
removed, the cells washed twice with buffer, and 3 ml of Eagle's medium containing the indi- 
cated serum supplement was added. After a 4 h incubation at 37°C, the medium was removed 
for measurement of radioactivity. Fresh medium of identical composition was added (3 ml), 
incubation was continued for a further period of 12 h, after which the radioactivity released 
was again measured. The final concentration of serum was 2.5%, and the total radioactivity 
in each dish was 20,000 cpm. 
enzyme activity. As  an initial  approach to such a  survey we have examined 
sera from more than  100 individuals. A  representative sampling is presented 
in Table V; there was a wide range of variation, the activity of the most active 
serum being approximately 30-fold higher than that of the least active. The 
fibrinolytic activity of serum from a  single donor (under standard conditions 
of cell factor concentration)appeared to be reproducible when blood was drawn 
at intervals over a period of months, and no distinctive pattern of activity has 
so far been correlated with any category of disease. The range of fibrinolytic 
activities seen with the different sera probably reflected the concentration of 
serum  inhibitors,  since  the  differences were  eliminated,  and  the  level  of fi- 
brinolysis was  increased,  by treatments  that  inactivated  serum  protease in- 
hibitors (e.g., brief exposure to pH 3). 
DISCUSSION 
Previous work with  avian and mammalian fibroblasts has established that 
primary cultures, transformed by either DNA or RNA viruses, produce levels 
of fibrinolytic activity much higher than those of the normal, control cultures. 
Since the publication of our initial reports (1, 2), comparably elevated levels of 
fibrinolysis have been observed in primary cultures of chemically induced rat 
hepatomas  and  mammary  carcinomas,  and  in  mouse mammary  carcinomas 1326  PROPERTIES  OF PLASMINOGEN  ACTIVATORS 
TABLE  V 
Effect o/Individual  Human  Sera on Fibrinolytic  Activity of Os~eosarcoma-Conditioned  Medium 
Test  Fluid  Serum Supplement  Radioactivity  Released 
c~  % o/total 
Fresh RPMI medium  D.L.  767  1.3 
Osteosarcoma conditioned medium  --  2,442  4.1 
"  D.L.  1,367  2.3 
"  D.E.  1,875  3.1 
"  L.O.  11,347  18.8 
"  Gz  29,342  48.8 
"  968  22,370  37.2 
"  440  25,954  43.2 
"  Gd  17,698  29.4 
"  Jhn  3,498  5.8 
"  2191  16,442  27.4 
"  D.R.  18,000  30.0 
"  CAL  862  1.4 
"  MEL  1,460  2.4 
Petri dishes (35 ram)  containing  [125I]fibrin (10 #g/cm; 6 X  105 cpm) were prepared  a s 
described previously. Conditioned or fresh medium was mixed with the individual  sera at a 
final concentration  of 2.5%, incubated  for 7.5 h, and then assayed for radioactivity. 
and  skin  tumors  induced,  respectively,  by viruses  and  by chemical  carcino- 
gens.* In these cases also, the enzyme activity produced by normal tissues was 
at,  or close to background levels.  The data presented  here  show that  the fi- 
brinolytic  activity  of  human  tumor  cell  lines  resembles  that  obtained  with 
transformed cells and primary cultures of malignant tissue from other species. 
The  similarities  include  the  following  properties  of  the  fibrinolytic  system: 
(a)  The fibrinolysis produced by human  cells requires  two factors: one is  re- 
leased  by the  cells,  and  the  other,  found in serum,  is plasminogen.  (b)  High 
levels of fibrinolysis are not observed with all sera. The activating sera for the 
human  system  are  monkey,  human,  mouse,  bovine,  and  horse.  Dog  serum, 
which  activates  fibrinolysis  with  transformed  hamster,  mouse,  and  rat  cells, 
permits  only minimal  levels  of  fibrinolysis  with  human  cells.  Fetal  bovine 
serum also is inhibitory, just as it is in all other systems studies so far.  (c)  The 
activity of the  human  cell  enzyme is  inhibited  by all  of the  trypsin-specific 
inhibitors  that  block the  fibrinolytic activity of other  cell  cultures.  (d)  The 
human cell factor, like those of transformed chick and hamster cells (4, 7), is a 
I)FP-sensitive serine protease  that functions  as a  potent plasminogen  activa- 
tor.  (e)  The concentration of activator produced  by the  three  human  tumor 
cell  lines  is in  the  same range  as  that  found in  transformed  chick fibroblast 
cultures. Based on measurements of [~H]DFP labeling,  the  level in melanoma- 
conditioned medium (20-200 pM)  is  somewhat  higher,  and  that  in  mesothe- 
4 Rifkin, D. B., A. Piperno, A. Tobia, and L. Ossowski. Unpublished observations. D.  B.  RZFKIN,  ~.  N.  LOEB,  G.  MOORE~  AND  E.  REICH  1327 
lioma-conditioned medium is somewhat lower (2-10 pM)  than in transformed 
chick cultures (10-30 pM). 
All of the above characteristics of the human fibrinolytic enzyme suggest 
that it is homologous with those previously observed in neoplastic and trans- 
formed  cultures from other  species.  These  similarities,  and  the  widespread 
occurrence  of  fibrinolysis and  disorders  of  coagulation  as  complications  of 
human metastatic disease (9-11),  suggest that a  fibrinolytic activity is likely 
to be associated with at least some human malignancies. 
In spite  of these  correlations  the formation of high levels of plasminogen 
activator cannot be taken as diagnostic of neoplasia. Although the concentra- 
tion in most normal tissue is generally low (1, 2, 4), a number of nonmalignant 
cells and cultures contain plasminogen activators at levels comparable to those 
found in neoplastic cells;  s these include granulocytes, activated macrophages, 
spermatozoa,  endometrium, and vampire bat  saliva,  in  addition to  the  cell 
lines of nonmalignant origin reported by other laboratories (12-14)  and in this 
paper. 
There is one reservation that applies specifically to the interpretation of the 
findings in this paper since they are based on the use of established cell lines, 
some of which had been maintained in culture for several years.  It seems possi- 
ble that the process of establishing cell lines in culture might favor the selec- 
tion of variants that produce  a  fibrinolytic activator. Therefore these  data 
while fully consistent with the results given by the animal cell models, are not 
by themselves as persuasive as those obtained either with primary cultures of 
embryo fibroblasts transformed in vitro, or with primary cultures of neoplastic 
tissues. In  the latter  two instances,  the  transformed cells  can be  compared 
with the normal parental  cell  type, or with adjacent normal tissues, respec- 
tively. Since the in vitro transformation of human cells proceeds with signifi- 
cantly lower efficiency than that of other mammalian cells, a firm correlation 
between  fibrinolysis  and  human  neoplasia  will  require  the  examination  of 
larger numbers of cell lines and transformants, as well as primary cultures de- 
rived from biopsies and other surgical specimens. Because plasminogen  acti- 
vator has already been detected at high  frequency in  fresh  samples  of hu- 
man tumors  (15), it is reasonable  to  expect  that  a  firm correlation  of  this 
activity with human malignancy may soon be forthcoming. 
SUMMARY 
A  series  of human cell  lines has been examined for fibrinolysis in culture. 
The sera that are activating for fibrinolysis by human cells are mouse, monkey, 
human, horse, and bovine. Individual human sera show considerable variation 
in the ability to activate fibrinolysis. In common with other neoplastic or trans- 
formed mammalian and  avian  cell  cultures,  human  cell  lines  of  neoplastic 
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origin produce substantial  amounts of plasminogen activator.  Several cultures 
of nonmalignant  origin also produce plasminogen  activator,  whereas  cultures 
obtained from trypsinized human embryos, or from human embryonic skin do 
not. The human melanoma plasminogen  activators  are of two kinds: a  major 
component with  a  tool  wt of 50,000,  and  a  minor  species  with  a  mol  wt  of 
approximately 60,000. Both are DFP sensitive,  serine proteases. 
We thank Dolores Pla, M. Whitbread, and J. O'Malley for excellent technical assistance. 
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